To read the full story, subscribe or sign in.

In the clinic

Dec. 8, 2017

Dicerna Pharmaceuticals Inc., of Cambridge, Mass., announced the dosing of the first subject in DCR-PHXC-101, a phase I trial of DCR-PHXC, the company's most advanced GalXC product candidate.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Dec. 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 23, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...